Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

13-06-2022 | ASCO 2022 | Conference coverage | Video

EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC

Jonathan Rosenberg takes us through the 2-year follow-up data from the EV-301 study comparing enfortumab vedotin with chemotherapy in previously treated patients with advanced urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

05-06-2022 | ASCO 2022 | Conference coverage | News

Enfortumab vedotin offers sustained benefit over 2 years in advanced UC

12-02-2021 | ASCO GU 2021 | Conference coverage | Video

EV-301: Enfortumab vedotin boosts advanced urothelial cancer survival

29-09-2021 | ESMO 2021 | Conference coverage | News

EV-301 update: Enfortumab vedotin benefit maintained in hard-to-treat subgroups

17-02-2021 | ASCO GU 2021 | Conference coverage | Video

Metastatic urothelial cancer: clinical insights into trial data
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits